Vistagen Therapeutics VTGN

NASDAQ VTGN
$0.19 -0.01 (-5.00%)
At close: Nov 19, 2026 · 4:00 PM EST

Vistagen Therapeutics (VTGN) stock price is $0.19, down 5.00% on the day, as of Nov 19, 2026. It has a market cap of $7.34Mn, and is classified in the Biotechnology industry (Healthcare sector).

Key Stats
Market Cap7.34 Mn
P/E-0.12
FCF (Yr)-66.44 Mn
ROA (Yr)-104.87
EV to EBIT2.50
Net Income (Yr)-69.69 Mn
Enterprise Value-151.60 Mn
Add ratio to table…

About

Vistagen Therapeutics, Inc. is a late stage biopharmaceutical company focused on discovering and developing non systemic intranasal product candidates known as pherines that target nose to brain neurocircuitry. The company’s pipeline includes five clinical stage pherine candidates: fasedienol for social anxiety disorder, itruvone for major depressive disorder, PH80 for menopausal hot flashes and premenstrual dysphoric disorder, PH15 for mental fatigue related cognitive and…

Read more ↓
Sector: Healthcare Sector rationale Vistagen Therapeutics is a biopharmaceutical company developing clinical-stage drug candidates such as fasedienol and itruvone for medical conditions like social anxiety disorder and major depressive disorder. Its revenue model is based on licensing and collaboration agreements for these pharmaceutical products, and its future customers are healthcare providers and pharmacies. Industry: Biotechnology Biotechnology Primary Vistagen is a biopharmaceutical company developing pherines, which are biological-based product candidates for conditions like social anxiety and major depressive disorder. Its revenue is currently derived from licensing and collaboration agreements, such as those with AffaMed Therapeutics and Fuji Pharma, which is characteristic of clinical-stage biotechnology developers. Classified using BQ-MICS CIK: 0001411685

Product and Service Breakdown of Revenue (2022)

History
Peer percentiles

How Vistagen Therapeutics ranks

Ranked against the 690 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 20, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −0.14xMedian 16.4x 8th
  • P/FCFNegative free cash flow −0.14xMedian 15.0x 6th
  • P/Operating cash flowNegative operating cash flow −0.14xMedian 14.9x 5th
  • P/S 3.68xMedian 8.18x 66th
  • P/B 0.59xMedian 2.03x 81st
  • P/Tangible book 0.59xMedian 2.23x 83rd
  • EV/EBITDANet cash exceeds market value 0.19xMedian 14.9x Not meaningful —
  • EV/EBITNet cash exceeds market value 0.19xMedian 17.0x Not meaningful —
  • EV/RevenueNet cash exceeds market value −4.73xMedian 6.79x Not meaningful —
  • EV/FCFNet cash exceeds market value 0.19xMedian 19.7x Not meaningful —
  • EV/Operating cash flowNet cash exceeds market value 0.19xMedian 15.4x Not meaningful —
  • PEG (3Y EPS CAGR)Negative earnings −0.01Median 0.40 Not meaningful —
Peer group

Peer Comparison

Companies in the Biotechnology
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 PETV PetVivo Holdings, Inc. 3,096.39 Bn-336,007.552.84 Mn0.00 Bn
2 LLY ELI LILLY & Co 1,202.70 Bn43.610.00 Mn49.50 Bn
3 JNJ Johnson & Johnson 649.77 Bn40.370.00 Mn44.65 Bn
4 ABBV AbbVie Inc. 507.00 Bn49.020.00 Mn80.90 Bn
5 MRK Merck & Co., Inc. 329.70 Bn134.410.00 Mn53.78 Bn
6 NVS Novartis Ag 291.91 Bn17.910.00 Mn-
7 AMGN Amgen Inc 236.26 Bn25.160.00 Mn54.01 Bn
8 VTGN Vistagen Therapeutics, Inc. 0.01 Bn-0.120.00 Mn-